![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Abu Hashim H, Alsherbini W, Bazeed M. 2012. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252.
- ACOG Committee on Practice Bulletins—Gynecology. 2012. Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin No 128. Obstetrics and Gynaecology 120:197–206.
- Agarwal N, Kriplani A. 2001. Medical management of dysfunctional uterine bleeding. International Journal of Gynecology and Obstetrics 75:199–201.
- Bruni V, Pontello V, Luisi S, Petraglia F. 2008. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing. Europeon Journal of Obstetrics and Gynecology and Reproductive Biology 139:65–71.
- Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. 2009. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. Journal of Obstetrics and Gynecology Canada 31:340–347.
- Fraser IS, McCarron G. 1991. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Australian and New Zealand Journal of Obstetrics and Gynaecology 31:66–70.
- Higham JM, O’Brien PM, Shaw RW. 1990. Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynecology 97:734–739
- Kaptein M, Zampaglione E. 2005. Expulsion of NuvaRing is low. Obstetrics and Gynaecology 105:56S.
- Laurikka-Routti M, Haukkamaa M, Heikinheimo O. 1990. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 2:111–120. “ http://www.ncbi.nlm.nih.gov/pubmed/2387151 ”
- Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ et al. 2006. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Human Reproduction 21:2304–2311.
- Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CHJ et al. 2005. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71:176–182.
- Roumen FJ, Apter D, Mulders TM, Dieben TO. 2001. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Human Reproduction 16:469–475.
- Roumen FJ, Dieben TO. 2006. Comparison of uterine concentrations of ethinylestradiol and etonogestrel — after use of a contraceptive vaginal ring and an oral contraceptive. Fertility and Sterility 85:57–62.
- Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. 2011. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 83:48–54.
- Singh RH, Blumenthal P. 2005. Hormonal management of abnormal uterine bleeding. In: Gabbe SG, Scott JR, editors, Clinical Obstetrics and Gynecology 48(2). Lippincott Williams & Wilkins. Philadelphia, PA. pp 337–352.
- Veres S, Miller L, Burington B. 2004. A comparison between the vaginal ring and oral contraceptives. Obstetrics and Gynecology 104:555–563.
- Wieder D, Pattimakiel L. 2010. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®). International Journal of Womens Health 2:401–409.